MeSH D016905 - gram-negative bacterial infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D001424:Bacterial infections
D016905:Â
Gram-negative bacterial infections
D000711:Anaplasmataceae infections
0 Companies
0 Drugs
Success rate
D001476:Bartonellaceae infections
0 Companies
0 Drugs
Success rate
D001885:Bordetella infections
0 Companies
0 Drugs
Success rate
D002006:Brucellosis
D002169:Campylobacter infections
D002694:Chlamydiaceae infections
D004756:Enterobacteriaceae infections
D005535:Foot rot
0 Companies
0 Drugs
Success rate
D007876:Legionellosis
D008193:Lyme disease
D009180:Mycoplasmatales infections
0 Companies
0 Drugs
Success rate
D011552:Pseudomonas infections
D011778:Q fever
0 Companies
0 Drugs
Success rate
D011906:Rat-bite fever
D012288:Rickettsiaceae infections
0 Companies
0 Drugs
Success rate
D013145:Spirochaetales infections
0 Companies
0 Drugs
Success rate
D014211:Treponemal infections
0 Companies
0 Drugs
Success rate
D014406:Tularemia
D014735:Vibrio infections
0 Companies
0 Drugs
Success rate
D016481:Helicobacter infections
D016866:Bacteroidaceae infections
D016870:Neisseriaceae infections
D016871:Pasteurellaceae infections
0 Companies
0 Drugs
Success rate
D019121:Burkholderia infections
0 Companies
0 Drugs
Success rate
D044225:Piscirickettsiaceae infections
0 Companies
0 Drugs
Success rate
D045824:Desulfovibrionaceae infections
0 Companies
0 Drugs
Success rate
D045825:Fusobacteriaceae infections
0 Companies
0 Drugs
Success rate
D045826:Flavobacteriaceae infections
0 Companies
0 Drugs
Success rate
D045827:Cytophagaceae infections
0 Companies
0 Drugs
Success rate
D045828:Moraxellaceae infections
D059707:Aliivibrio infections
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Merck & Co | Cilastatin, Imipenem, Relebactam | Recarbrio |  | 2020-02-13 |  |  |
| Pfizer | Avibactam, Ceftazidime | Zavicefta |  | 2016-06-23 | $511 M | Y2023 |
| Shionogi | Cefiderocol | Fetcroja |  | 2020-04-23 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
0%0/7
Phase 3
84%16/19
Approved: 15Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use